News | July 24, 2012

Head-to-Head Study Compares Navidea’s AZD4694 to the Gold Standard for Imaging Beta Amyloid Protein

Trial examines AZD4694 performance characteristics and blinded reader confidence when used as an aid in diagnosing Alzheimer's Disease

July 24, 2012 — Navidea Biopharmaceuticals Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced that clinical data from a head-to head study comparing its amyloid imaging candidate, AZD4694, to the benchmark amyloid imaging agent, 11C-PiB (PiB), was presented at the Alzheimer's Association International Conference (AAIC) in Vancouver, Canada by Professor Christopher Rowe, MD, FRACP, Director of the Department of Nuclear Medicine and Centre for PET at Austin Health, Melbourne, Australia.

In addition, on Friday, July 13, 2012, Navidea received approval for its Phase 2 AZD4694 protocol from the New England Institutional Review Board (IRB), a centralized IRB that oversees the approval of clinical protocols for investigational drugs for multiple research organizations. Trial enrollment is expected to commence in the coming months.

Rowe’s talk was entitled, “Head to head comparison of 11C-PiB and 18F-AZD4694 for A? imaging in ageing and dementia.” The presentation highlighted new results from a blinded-reader analysis which examined imaging characteristics such as binding kinetics, standard uptake value ratios (SUVR) in three time intervals, and non-specific white-matter retention for these agents obtained in the same subjects. The two agents, 11C-PiB and 18F-AZD4694, were employed to sequentially image the brains of forty-five participants (25 healthy elderly controls, 10 subjects with Mild Cognitive Impairment, 7 subjects with probable Alzheimer’s Disease and 3 subjects with fronto-temporal dementia). The mean age of the participant groups was about 74, except that the three fronto-temporal dementia patients averaged about 68 years old. Cognitive impairments in the patient groups showed mean scores on the Mini-Mental State Examination of 24 to 27 and were within the mild to moderate range.

As previously reported, quantitative measures, such as SUVR, of 18F-AZD4694 binding to cortical amyloid plaques are essentially identical to 11C-PiB. A very tight performance correlation was observed (r=0.98, p<0.0001; slope 0.95). Visually, images obtained in the same patient with the same scan times, the same data processing and the same display scales, were identical. 18F-AZD4694 had comparable binding kinetics and dynamic range of SUVR to the benchmark 11C-PiB as well as similar high values of cortex to white matter ratios. Using the PiB as reference, the sensitivity, specificity, and overall accuracy within the 40 to 60 minute readings ranged from 94 percent to 98 percent. Additionally, confidence levels from the blinded readers averaged 93 percent using 40 to 60 minute readings, indicating a high degree of confidence in the interpretability of the images within this time range.

Related Content

FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
High Prevalence of Atherosclerosis Found in Lower Risk Patients
News | Magnetic Resonance Imaging (MRI) | June 08, 2018
Whole-body magnetic resonance angiography (MRA) found a surprisingly high prevalence of atherosclerosis in people...
Lung Decision Precision
News | Lung Cancer | June 04, 2018
For smokers and former smokers, the threat of lung cancer always lurks in the shadows.
Overlay Init